Evolution of myocardial steatosis in high cardiovascular risk T2DM patients treated by GLP1 receptor agonists: LICAS study.

Fiche publication

Date publication

février 2025

Journal

Diabetes research and clinical practice

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FOURNEL Isabelle , Pr PETIT Jean-Michel , Pr COCHET Alexandre

Tous les auteurs :
Houbachi L, Walker PM, Fournel I, Ksiazek E, Petit JM, Cochet A, Leclercq T, Roger A, Simoneau I, Bouillet B, Guenancia C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39900263

Résumé

We hypothesized that the reduction of intramyocardial fat content may be involved in the cardioprotective effect of glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with type 2 diabetes (T2D). Therefore, we aimed to evaluate the change in intramyocardial triglyceride content in T2D patients treated with GLP1-RA.